Lq3 Pharmaceuticals launches with a series A round of $10m.
Liquidia Technologies, a spin-out of University of North Carolina at Chapel Hill, has itself spun out a new company, Lq3 Pharmaceuticals. It is the second pharmaceutical company to come out of Liqudia.
Lq3 has launched with a series A round worth $10m, led by Canaan Partners, a Californian venture capital firm with a focus on healthcare and technology. Canaan already invested in eye disease expert Envisia Therapeutics, Liquidia’s first spin-out.
Lq3 will utilise Liquidia’s particle replication in non-wetting templates (Print)…
